These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 28629761)

  • 21. Innovative Clinical Perspectives for CIK Cells in Cancer Patients.
    Introna M; Correnti F
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29370095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of NKG2D in cytokine-induced killer cells against multiple myeloma cells.
    Lu X; Zhu A; Cai X; Jia Z; Han W; Ma L; Zhou M; Qian K; Cen L; Chen B
    Cancer Biol Ther; 2012 Jun; 13(8):623-9. PubMed ID: 22555808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells.
    Niu C; Jin H; Li M; Xu J; Xu D; Hu J; He H; Li W; Cui J
    BMC Immunol; 2015 Oct; 16():61. PubMed ID: 26458364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polysaccharides from Hedyotis diffusa enhance the antitumor activities of cytokine-induced killer cells.
    Ma C; Wei Y; Liu Q; Xin Y; Cao G; Wang X; Yang P
    Biomed Pharmacother; 2019 Sep; 117():109167. PubMed ID: 31387180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation.
    Sangiolo D; Mesiano G; Carnevale-Schianca F; Piacibello W; Aglietta M; Cignetti A
    Expert Opin Biol Ther; 2009 Jul; 9(7):831-40. PubMed ID: 19463075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CIK as therapeutic agents against tumors.
    Introna M
    J Autoimmun; 2017 Dec; 85():32-44. PubMed ID: 28679475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer Immunotherapy with Cytokine-Induced Killer Cells.
    Mata-Molanes JJ; Sureda González M; Valenzuela Jiménez B; Martínez Navarro EM; Brugarolas Masllorens A
    Target Oncol; 2017 Jun; 12(3):289-299. PubMed ID: 28474278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity.
    Nishimura R; Baker J; Beilhack A; Zeiser R; Olson JA; Sega EI; Karimi M; Negrin RS
    Blood; 2008 Sep; 112(6):2563-74. PubMed ID: 18565854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dendritic Cells Therapy with Cytokine-Induced Killer Cells and Activated Cytotoxic T Cells Attenuated Th2 Bias Immune Response.
    Li C; Zhu D; Zhao Y; Guo Q; Sun W; Li L; Gao D; Zhao P
    Immunol Invest; 2020 Jul; 49(5):522-534. PubMed ID: 31793363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma.
    Giraudo L; Cattaneo G; Gammaitoni L; Iaia I; Donini C; Massa A; Centomo ML; Basiricò M; Vigna E; Pisacane A; Picciotto F; Berrino E; Marchiò C; Merlini A; Paruzzo L; Poletto S; Caravelli D; Biolato AM; Bortolot V; Landoni E; Ventin M; Ferrone CR; Aglietta M; Dotti G; Leuci V; Carnevale-Schianca F; Sangiolo D
    J Exp Clin Cancer Res; 2023 Nov; 42(1):310. PubMed ID: 37993874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human interferon-alpha increases the cytotoxic effect of CD56(+) cord blood-derived cytokine-induced killer cells on human B-acute lymphoblastic leukemia cell lines.
    Durrieu L; Gregoire-Gauthier J; Dieng MM; Fontaine F; le Deist F; Haddad E
    Cytotherapy; 2012 Nov; 14(10):1245-57. PubMed ID: 22974386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.
    Du SH; Li Z; Chen C; Tan WK; Chi Z; Kwang TW; Xu XH; Wang S
    PLoS One; 2016; 11(9):e0161820. PubMed ID: 27598655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
    Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
    Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ex vivo-activated MHC-unrestricted immune effectors for cancer adoptive immunotherapy.
    Leuci V; Mesiano G; Gammaitoni L; Todorovic M; Giraudo L; Carnevale-Schianca F; Aglietta M; Sangiolo D
    Anticancer Agents Med Chem; 2014 Feb; 14(2):211-22. PubMed ID: 24237224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures.
    Bonanno G; Iudicone P; Mariotti A; Procoli A; Pandolfi A; Fioravanti D; Corallo M; Perillo A; Scambia G; Pierelli L; Rutella S
    J Transl Med; 2010 Dec; 8():129. PubMed ID: 21138560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.
    Shi S; Wang R; Chen Y; Song H; Chen L; Huang G
    PLoS One; 2013; 8(6):e65757. PubMed ID: 23799045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The CIK cells stimulated with combination of IL-2 and IL-15 provide an improved cytotoxic capacity against human lung adenocarcinoma.
    Wei C; Wang W; Pang W; Meng M; Jiang L; Xue S; Xie Y; Li R; Hou Z
    Tumour Biol; 2014 Mar; 35(3):1997-2007. PubMed ID: 24104501
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers.
    Sangiolo D; Martinuzzi E; Todorovic M; Vitaggio K; Vallario A; Jordaney N; Carnevale-Schianca F; Capaldi A; Geuna M; Casorzo L; Nash RA; Aglietta M; Cignetti A
    Int Immunol; 2008 Jul; 20(7):841-8. PubMed ID: 18469328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Roles of NKG2D in cytokine-induced killer (CIK) against hematological malignant cells lines].
    He JY; Jia ZX; Cai XH; Han WM; Xiao R; Ma LD; Lu XZ; Zhou M; Chen BA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1380-4. PubMed ID: 24370015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.